The proposed duties—linked to India’s high tariffs, non-tariff barriers, and Russia ties—could disrupt key sectors like ...

Reported EPS is $0.2429 EPS, expectations were $0.63. Operator: Hello, and welcome to the Teva Pharmaceutical Industries ...

In recent health news, WuXi Apptec plans a $980 million share expansion, nursing strikes erupt in Nigeria, Teva ...

The global Cancer Pain Market is valued at USD 6983.5 Million in 2024 and is projected to reach a value of USD 12031.1 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 5.1% between 2025 and ...

Teva Pharmaceutical Industries Ltd. agreed to end its lawsuit alleging Amneal Pharmaceuticals of New York LLC and its affiliates infringed patents for the pharmaceutical giant’s asthma inhaler. Judge ...

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Teva Pharmaceuticals swung to a second-quarter profit though narrowed its full-year adjusted earnings guidance. The Israeli based pharmaceutical company posted a second-quarter profit of $282 million, ...

Parkinson's Disease Therapeutics Market The Parkinson's therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8 ...

Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of ...